0001209191-24-003241.txt : 20240213
0001209191-24-003241.hdr.sgml : 20240213
20240213190337
ACCESSION NUMBER: 0001209191-24-003241
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240209
FILED AS OF DATE: 20240213
DATE AS OF CHANGE: 20240213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mauro David J
CENTRAL INDEX KEY: 0001621172
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 24630985
MAIL ADDRESS:
STREET 1: 36 TERRELL DRIVE
CITY: WASHINGTON CROSS
STATE: PA
ZIP: 18977
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-09
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001621172
Mauro David J
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
Chief Medical Officer
0
Class A Common Stock
2024-02-09
4
A
0
6040
0.00
A
196753
D
Class A Common Stock
2024-02-09
4
A
0
49768
0.00
A
246521
D
Class A Common Stock
2024-02-09
4
F
0
1892
10.09
D
244629
D
Stock Option (Right to Buy)
8.77
2033-06-01
Class A Common Stock
381426
381426
D
Stock Option (RIght to Buy)
10.09
2024-02-09
4
A
0
99537
0.00
A
2034-02-09
Class A Common Stock
99537
99537
D
This RSU vested immediately upon the grant date.
This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/ Jonathan Golightly, attorney-in-fact
2024-02-13